45 filings
6-K
HCM
HUTCHMED (China) Limited
31 Dec 19
Current report (foreign)
6:27am
6-K
HCM
HUTCHMED (China) Limited
20 Dec 19
Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China
6:09am
6-K
HCM
HUTCHMED (China) Limited
12 Dec 19
Current report (foreign)
6:06am
6-K
HCM
HUTCHMED (China) Limited
29 Nov 19
Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China
6:12am
6-K
HCM
HUTCHMED (China) Limited
25 Nov 19
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
6:21am
6-K
5l95034uy6
12 Nov 19
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
6:36am
6-K
xom1vjispmriigutikn
17 Oct 19
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
6:14am
6-K
jvkr385r3
10 Oct 19
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
7:05am
6-K
yg4rd2i24a2at4 am
4 Oct 19
Current report (foreign)
6:11am
6-K
5flqdjclr5s znrnu
3 Oct 19
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)I
6:29am
6-K
rpzjqsm3r2zzx4k2wk
30 Sep 19
Current report (foreign)
4:16pm
6-K
ukle0ac84n7yx
30 Sep 19
Current report (foreign)
9:13am
6-K
j0r9t2vtvjzkho1rk
30 Sep 19
CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
7:30am
6-K
2eu3ha
30 Sep 19
Current report (foreign)
7:24am
6-K
8zfj5dm
30 Sep 19
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
6:13am
6-K
re6p32vjn
25 Sep 19
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
7:21am
6-K
q0p582
18 Sep 19
Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
6:08am
6-K
5njjoqy itd9
3 Sep 19
Current report (foreign)
6:18am
6-K
6gu xxcw7hk6hd1
30 Aug 19
Current report (foreign)
6:24am
6-K
jwqo3vs90vd4 4ei3zi
23 Aug 19
Current report (foreign)
6:27am